Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ALQA's Cash to Debt is ranked higher than
98% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. ALQA: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ALQA' s 10-Year Cash to Debt Range
Min: 0.05  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.69
ALQA's Equity to Asset is ranked higher than
60% of the 562 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. ALQA: 0.69 )
Ranked among companies with meaningful Equity to Asset only.
ALQA' s 10-Year Equity to Asset Range
Min: 0.64  Med: 0.92 Max: 0.99
Current: 0.69
0.64
0.99
Interest Coverage No Debt
ALQA's Interest Coverage is ranked higher than
97% of the 374 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2065.49 vs. ALQA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ALQA' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 6
Z-Score: 2.71
M-Score: -0.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -385.83
ALQA's Operating margin (%) is ranked lower than
94% of the 658 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.76 vs. ALQA: -385.83 )
Ranked among companies with meaningful Operating margin (%) only.
ALQA' s 10-Year Operating margin (%) Range
Min: -1119.69  Med: -464.77 Max: -51.07
Current: -385.83
-1119.69
-51.07
Net-margin (%) -381.53
ALQA's Net-margin (%) is ranked lower than
94% of the 659 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.90 vs. ALQA: -381.53 )
Ranked among companies with meaningful Net-margin (%) only.
ALQA' s 10-Year Net-margin (%) Range
Min: -1222.3  Med: -465.38 Max: -52.73
Current: -381.53
-1222.3
-52.73
ROE (%) -113.33
ALQA's ROE (%) is ranked lower than
95% of the 685 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.19 vs. ALQA: -113.33 )
Ranked among companies with meaningful ROE (%) only.
ALQA' s 10-Year ROE (%) Range
Min: -714.29  Med: -105.81 Max: -16.22
Current: -113.33
-714.29
-16.22
ROA (%) -87.48
ALQA's ROA (%) is ranked lower than
97% of the 705 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. ALQA: -87.48 )
Ranked among companies with meaningful ROA (%) only.
ALQA' s 10-Year ROA (%) Range
Min: -2368.45  Med: -140.97 Max: -15.45
Current: -87.48
-2368.45
-15.45
ROC (Joel Greenblatt) (%) -1588.62
ALQA's ROC (Joel Greenblatt) (%) is ranked lower than
92% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.97 vs. ALQA: -1588.62 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALQA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -287600  Med: -10918.63 Max: -55.94
Current: -1588.62
-287600
-55.94
Revenue Growth (3Y)(%) -5.40
ALQA's Revenue Growth (3Y)(%) is ranked lower than
80% of the 541 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. ALQA: -5.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALQA' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 0.00 Max: -5.4
Current: -5.4
EBITDA Growth (3Y)(%) -15.90
ALQA's EBITDA Growth (3Y)(%) is ranked lower than
77% of the 483 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. ALQA: -15.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ALQA' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 24.10 Max: 106.5
Current: -15.9
0
106.5
EPS Growth (3Y)(%) -15.90
ALQA's EPS Growth (3Y)(%) is ranked lower than
74% of the 451 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. ALQA: -15.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALQA' s 10-Year EPS Growth (3Y)(%) Range
Min: -46.8  Med: 30.30 Max: 113.8
Current: -15.9
-46.8
113.8
» ALQA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ALQA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.98
ALQA's P/B is ranked lower than
62% of the 671 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.55 vs. ALQA: 4.98 )
Ranked among companies with meaningful P/B only.
ALQA' s 10-Year P/B Range
Min: 0.53  Med: 1.90 Max: 23.24
Current: 4.98
0.53
23.24
P/S 12.27
ALQA's P/S is ranked lower than
84% of the 649 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.43 vs. ALQA: 12.27 )
Ranked among companies with meaningful P/S only.
ALQA' s 10-Year P/S Range
Min: 4.65  Med: 12.21 Max: 39.22
Current: 12.27
4.65
39.22
Current Ratio 3.33
ALQA's Current Ratio is ranked higher than
64% of the 608 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.29 vs. ALQA: 3.33 )
Ranked among companies with meaningful Current Ratio only.
ALQA' s 10-Year Current Ratio Range
Min: 0.04  Med: 1.42 Max: 96.93
Current: 3.33
0.04
96.93
Quick Ratio 2.97
ALQA's Quick Ratio is ranked higher than
68% of the 607 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. ALQA: 2.97 )
Ranked among companies with meaningful Quick Ratio only.
ALQA' s 10-Year Quick Ratio Range
Min: 0.04  Med: 1.11 Max: 96.93
Current: 2.97
0.04
96.93
Days Inventory 105.41
ALQA's Days Inventory is ranked higher than
56% of the 621 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.49 vs. ALQA: 105.41 )
Ranked among companies with meaningful Days Inventory only.
ALQA' s 10-Year Days Inventory Range
Min: 11.87  Med: 44.34 Max: 106.73
Current: 105.41
11.87
106.73
Days Sales Outstanding 81.23
ALQA's Days Sales Outstanding is ranked lower than
56% of the 592 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.86 vs. ALQA: 81.23 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALQA' s 10-Year Days Sales Outstanding Range
Min: 13.55  Med: 33.21 Max: 73.9
Current: 81.23
13.55
73.9

Valuation & Return

vs
industry
vs
history
Price/Net Cash 24.90
ALQA's Price/Net Cash is ranked lower than
69% of the 181 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.71 vs. ALQA: 24.90 )
Ranked among companies with meaningful Price/Net Cash only.
ALQA' s 10-Year Price/Net Cash Range
Min: 5.09  Med: 17.40 Max: 3325
Current: 24.9
5.09
3325
Price/Net Current Asset Value 11.86
ALQA's Price/Net Current Asset Value is ranked lower than
65% of the 384 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.66 vs. ALQA: 11.86 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ALQA' s 10-Year Price/Net Current Asset Value Range
Min: 4.78  Med: 15.38 Max: 3325
Current: 11.86
4.78
3325
Price/Tangible Book 9.58
ALQA's Price/Tangible Book is ranked lower than
79% of the 620 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.32 vs. ALQA: 9.58 )
Ranked among companies with meaningful Price/Tangible Book only.
ALQA' s 10-Year Price/Tangible Book Range
Min: 4.37  Med: 8.45 Max: 2406.3
Current: 9.58
4.37
2406.3
Price/Median PS Value 0.99
ALQA's Price/Median PS Value is ranked higher than
76% of the 606 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.40 vs. ALQA: 0.99 )
Ranked among companies with meaningful Price/Median PS Value only.
ALQA' s 10-Year Price/Median PS Value Range
Min: 0.53  Med: 0.98 Max: 2.88
Current: 0.99
0.53
2.88
Earnings Yield (Greenblatt) (%) -21.44
ALQA's Earnings Yield (Greenblatt) (%) is ranked lower than
94% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.30 vs. ALQA: -21.44 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALQA' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -58.1  Med: 0.00 Max: 0
Current: -21.44
-58.1
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:WST, BAX, COV, TMO, COO » details
Alliqua BioMedical Inc a Florida corporation formed on October 21, 1997. It is a biomedical company through its subsidiary providing advanced wound care solutions. The Company's core business includes; advanced wound care and contract manufacturing. The Company develops, manufactures and markets high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. Its subsidiary manufactures and markets its hydrogel products. Its products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies. Together, these technologies enable it to produce gels that can satisfy rigid tolerance specifications with respect to a range of physical characteristics (e.g., thickness, water content, adherence, absorption, moisture vapor transmission rate (a measure of the passage of water vapor through a substance) and release rate) while maintaining product integrity. In July 2012, it began to market two proprietary products, SilverSeal, a hydrogel wound dressing with silver coated fibers, and Hydress, an over-the-counter hydrogel wound dressing. It supplies these gels mainly to the wound care segment of the healthcare industry. The Company's SilverSeal and Hydress dressings are each currently available in two sizes and are used to provide and maintain a moist wound environment. SilverSeal dressings also provide an antimicrobial barrier. On November 14, 2013 Company entered into a license, marketing and development agreement with Anthrogenesis Corporation, Celgene Cellular Therapeutics ("CCT"), an affiliate of Celgene Corporation, pursuant to which CCT granted an exclusive, royalty-bearing license in its intellectual property related to certain placental based products, including the wound care products Extracellular Matrix ("ECM"), a suite of advanced wound management products made from extracellular matrix derived from the human placenta and Biovance, a collagen-based decellularized and dehydrated topical wound covering produced from human amniotic membrane for the management of non-infected partial- and full-thickness wounds; and also into a supply agreement with CCT, pursuant to which CCT will supply Company with the entire requirement of Biovance for distribution and sale in the United States. The Company's medical devices are subject to the U.S. Food and Drug Administration's general controls, which include compliance with the applicable portions of the U.S. Food and Drug Administration's Quality System Regulation, facility registration and product listing, reporting of adverse medical events, and appropriate, truthful and non-misleading labeling, advertising, and promotional materials. It is subject to various laws and governmental regulations concerning environmental matters and employee safety and health in the U
» More Articles for ALQA

Headlines

Articles On GuruFocus.com
Market Overlooks Alliqua’s First MAC Coverage Apr 21 2015 
Celleration Acquisition Just the Start of Alliqua’s M&A Strategy Feb 04 2015 

More From Other Websites
Alliqua BioMedical, Inc. to Announce Second Quarter of Fiscal Year 2015 Results on August 6th Jul 14 2015
Alliqua BioMedical, Inc. to Announce Second Quarter of Fiscal Year 2015 Results on August 6th Jul 14 2015
Today's Bell Ringer, July 6 Jul 06 2015
Alliqua BioMedical, Inc. (Nasdaq: ALQA) to Ring The Nasdaq Stock Market Opening Bell Jul 02 2015
Alliqua BioMedical, Inc. (Nasdaq: ALQA) to Ring The Nasdaq Stock Market Opening Bell Jul 02 2015
Alliqua BioMedical, Inc. to Ring the Nasdaq Stock Market Opening Bell on July 6th Jun 29 2015
Alliqua BioMedical, Inc. Announces the Publication of Results From a Biovance(R) Use Registry Study... Jun 25 2015
ALLIQUA BIOMEDICAL, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 25 2015
Alliqua BioMedical, Inc. Announces the Publication of Results From a Biovance(R) Use Registry Study... Jun 25 2015
ALLIQUA BIOMEDICAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other... Jun 09 2015
Alliqua Biomedical (ALQA) Shares March Higher, Can It Continue? - Tale of the Tape Jun 09 2015
Alliqua BioMedical, Inc. Appoints Nino Pionati as Chief Strategy and Marketing Officer Jun 03 2015
Alliqua BioMedical, Inc. Appoints Nino Pionati as Chief Strategy and Marketing Officer Jun 03 2015
ALLIQUA BIOMEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion... Jun 01 2015
Alliqua BioMedical, Inc. Announces Closing of Celleration, Inc. Acquisition Jun 01 2015
Alliqua BioMedical, Inc. Announces Closing of Celleration, Inc. Acquisition Jun 01 2015
ALLIQUA BIOMEDICAL, INC. Financials May 27 2015
10-Q for Alliqua, Inc. May 16 2015
Alliqua reports 1Q loss May 14 2015
Alliqua reports 1Q loss May 14 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK